1. Home
  2. MURA vs INLX Comparison

MURA vs INLX Comparison

Compare MURA & INLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • INLX
  • Stock Information
  • Founded
  • MURA 2013
  • INLX 1996
  • Country
  • MURA Ireland
  • INLX United States
  • Employees
  • MURA N/A
  • INLX N/A
  • Industry
  • MURA
  • INLX EDP Services
  • Sector
  • MURA
  • INLX Technology
  • Exchange
  • MURA Nasdaq
  • INLX Nasdaq
  • Market Cap
  • MURA 36.0M
  • INLX 40.8M
  • IPO Year
  • MURA N/A
  • INLX N/A
  • Fundamental
  • Price
  • MURA $2.09
  • INLX $10.33
  • Analyst Decision
  • MURA Buy
  • INLX
  • Analyst Count
  • MURA 2
  • INLX 0
  • Target Price
  • MURA $6.00
  • INLX N/A
  • AVG Volume (30 Days)
  • MURA 103.1K
  • INLX 6.5K
  • Earning Date
  • MURA 11-04-2025
  • INLX 11-13-2025
  • Dividend Yield
  • MURA N/A
  • INLX N/A
  • EPS Growth
  • MURA N/A
  • INLX N/A
  • EPS
  • MURA N/A
  • INLX N/A
  • Revenue
  • MURA N/A
  • INLX $17,127,854.00
  • Revenue This Year
  • MURA N/A
  • INLX N/A
  • Revenue Next Year
  • MURA N/A
  • INLX $14.19
  • P/E Ratio
  • MURA N/A
  • INLX N/A
  • Revenue Growth
  • MURA N/A
  • INLX N/A
  • 52 Week Low
  • MURA $0.95
  • INLX $8.74
  • 52 Week High
  • MURA $4.74
  • INLX $16.50
  • Technical
  • Relative Strength Index (RSI)
  • MURA 52.55
  • INLX 29.70
  • Support Level
  • MURA $2.06
  • INLX $10.85
  • Resistance Level
  • MURA $2.10
  • INLX $11.10
  • Average True Range (ATR)
  • MURA 0.01
  • INLX 0.22
  • MACD
  • MURA 0.00
  • INLX -0.19
  • Stochastic Oscillator
  • MURA 66.67
  • INLX 0.00

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

Share on Social Networks: